EMD Serono appoints U.S. CMO

Wednesday, September 30, 2015

EMD Serono, the U.S. biopharmaceutical business of Germany-based Merck, has appointed Joseph Leveque, M.D., as U.S. chief medical officer. Leveque will be responsible for working with the regulatory, medical and development teams to enhance EMD Serono’s clinical presence in the U.S. and to drive the execution of crucial medical initiatives.

[Read More]

Cephalon shows positive results for Nuvigil

Friday, May 6, 2011

Cephalon has positive results from a phase IV trial of nearly 400 people with excessive sleepiness associated with shift work disorder.  In the trial, Nuvigil (armodafinil) tablets improved shift-workers’ overall clinical condition late in their shifts (i.e., 4:00 a.m. to 8:00 a.m.), including the commute home, compared to placebo.

[Read More]

Teva aquires Cephalon

Monday, May 2, 2011

Teva Pharmaceutical and Cephalon have unanimously approved a definitive agreement under which Teva will acquire all of the outstanding shares of Cephalon for $81.50 per share in cash, or a total enterprise value of approximately $6.8 billion. The transaction is not conditioned on financing and is expected to be completed in the third quarter of 2011.

[Read More]